Capsule endoscopy (CE), introduced in 2000 and FDA-approved in 2001, remains a valuable tool for diagnosing gastrointestinal (GI) lesions, particularly in areas inaccessible to traditional endoscopy. While CE offers non-invasive imaging and improves detection of small bowel diseases and obscure GI bleeding, its widespread use is hindered by limitations such as lack of therapeutic capabilities, inability to obtain biopsies, reliance on peristalsis for movement, and time-consuming image interpretation.
Trending
- Cylinder Health strengthens gut-brain leadership with new Head of Gut-Brain Health and Clinical Advisory Board appointment (Cylinder Health)
- The new era of physician independence (Medical Economics)
- “Don’t Take Shortcuts,” Endoscopy Researcher Advises (GI & Hepatology News)
- Olympus Unveils Corporate Strategy (Olympus)
- Unlocking value creation in healthcare: How AI can reverse private equity’s return challenges – Part 1: HealthTech and tech-enabled services (Lexology)
- 5 highest-paid gastroenterologists in New York City (Becker’s GI & Endoscopy)
- And Your 2025 Healio Disruptive Innovators Are … (Healio)
- The Hype and Limits of At-Home Gut Microbiome Tests (U.S. News)
